Gabelli Funds LLC Has $2.13 Million Holdings in Embecta Corp. $EMBC

Gabelli Funds LLC trimmed its holdings in shares of Embecta Corp. (NASDAQ:EMBC) by 29.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 151,253 shares of the company’s stock after selling 62,199 shares during the period. Gabelli Funds LLC owned approximately 0.26% of Embecta worth $2,134,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Embecta by 7.9% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,005 shares of the company’s stock valued at $145,000 after acquiring an additional 1,093 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Embecta by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock worth $209,000 after purchasing an additional 1,110 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after purchasing an additional 1,159 shares in the last quarter. Laurel Wealth Advisors LLC increased its stake in Embecta by 754.3% in the second quarter. Laurel Wealth Advisors LLC now owns 1,871 shares of the company’s stock valued at $193,000 after purchasing an additional 1,652 shares in the last quarter. Finally, GSA Capital Partners LLP raised its holdings in shares of Embecta by 11.1% during the third quarter. GSA Capital Partners LLP now owns 27,525 shares of the company’s stock valued at $388,000 after purchasing an additional 2,760 shares during the period. Institutional investors own 93.83% of the company’s stock.

Embecta Stock Performance

EMBC stock opened at $9.09 on Wednesday. The company has a market capitalization of $538.31 million, a P/E ratio of 3.84 and a beta of 1.10. Embecta Corp. has a 52-week low of $8.81 and a 52-week high of $15.55. The business has a 50-day simple moving average of $10.97 and a two-hundred day simple moving average of $12.67.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.67 by $0.04. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The firm had revenue of $261.20 million during the quarter, compared to the consensus estimate of $258.07 million. During the same period in the prior year, the business posted $0.65 earnings per share. The company’s quarterly revenue was down .3% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, sell-side analysts forecast that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 17th. Investors of record on Friday, February 27th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date of this dividend is Friday, February 27th. Embecta’s dividend payout ratio is presently 25.32%.

Analysts Set New Price Targets

EMBC has been the topic of a number of research analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, BTIG Research reiterated a “buy” rating and issued a $25.00 price target on shares of Embecta in a report on Friday, February 6th. One research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $18.50.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.